Antibody–drug conjugates come of age in oncology
C Dumontet, JM Reichert, PD Senter… - Nature Reviews Drug …, 2023 - nature.com
Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …
Therapeutic peptides: current applications and future directions
L Wang, N Wang, W Zhang, X Cheng, Z Yan… - Signal transduction and …, 2022 - nature.com
Peptide drug development has made great progress in the last decade thanks to new
production, modification, and analytic technologies. Peptides have been produced and …
production, modification, and analytic technologies. Peptides have been produced and …
Radiotheranostics in oncology: current challenges and emerging opportunities
Structural imaging remains an essential component of diagnosis, staging and response
assessment in patients with cancer; however, as clinicians increasingly seek to …
assessment in patients with cancer; however, as clinicians increasingly seek to …
Advancing therapy for neuroblastoma
B Qiu, KK Matthay - Nature Reviews Clinical Oncology, 2022 - nature.com
Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course
ranging from localized or spontaneously regressing to widely metastatic disease …
ranging from localized or spontaneously regressing to widely metastatic disease …
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival …
Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Trends in peptide drug discovery
Since the introduction of insulin almost a century ago, more than 80 peptide drugs have
reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis …
reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis …
Molecular imaging in oncology: Current impact and future directions
The authors define molecular imaging, according to the Society of Nuclear Medicine and
Molecular Imaging, as the visualization, characterization, and measurement of biological …
Molecular Imaging, as the visualization, characterization, and measurement of biological …
Radiation therapy‐associated toxicity: Etiology, management, and prevention
K Wang, JE Tepper - CA: a cancer journal for clinicians, 2021 - Wiley Online Library
Radiation therapy (RT) is a curative treatment for many malignancies and provides effective
palliation in patients with tumor‐related symptoms. However, the biophysical effects of RT …
palliation in patients with tumor‐related symptoms. However, the biophysical effects of RT …
Liver metastases
Liver metastases are commonly detected in a range of malignancies including colorectal
cancer (CRC), pancreatic cancer, melanoma, lung cancer and breast cancer, although CRC …
cancer (CRC), pancreatic cancer, melanoma, lung cancer and breast cancer, although CRC …